Assignee
GENZYME CORP
US·693 granted patents·392 pending applications·21,700 citations·filing 1984–2025
Top patents by PatentIndex Score
1,085 records- 0198US11911440B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted Feb 27, 2024·5 cites·20 claims
- 0298US7846729B2Metabolically activated recombinant viral vectors and methods for their preparation and useGENZYME CORP·Filed 2007·Granted Dec 7, 2010·75 cites·9 claims
- 0398US7811757B2Methods for disease detectionGENZYME CORP·Filed 2006·Granted Oct 12, 2010·100 cites·12 claims
- 0498US7785888B2Metabolically activated recombinant viral vectors and methods for their preparation and useGENZYME CORP·Filed 2006·Granted Aug 31, 2010·74 cites·6 claims
- 0598US7704492B2Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virionsGENZYME CORP·Filed 2008·Granted Apr 27, 2010·45 cites·17 claims
- 0698US7341720B2Targeting of glycoprotein therapeuticsGENZYME CORP·Filed 2006·Granted Mar 11, 2008·85 cites·18 claims
- 0798US6521223B1Single phase gels for the prevention of adhesionsGENZYME CORP·Filed 2000·Granted Feb 18, 2003·206 cites·15 claims
- 0898US6162208AArticulating endoscopic implant rotator surgical apparatus and method for using sameGENZYME CORP·Filed 1998·Granted Dec 19, 2000·2.2k cites·33 claims
- 0997US11975043B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted May 7, 2024·3 cites·33 claims
- 1097US9790268B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2014·Granted Oct 17, 2017·29 cites·39 claims
- 1197US8383780B2Antibodies to TGFβGENZYME CORP·Filed 2010·Granted Feb 26, 2013·66 cites·6 claims
- 1297US7704721B2Compositions and methods to prevent AAV vector aggregationGENZYME CORP·Filed 2005·Granted Apr 27, 2010·74 cites·11 claims
- 1397US7427396B2AAV vectors for gene delivery to the lungGENZYME CORP·Filed 2005·Granted Sep 23, 2008·149 cites·4 claims
- 1497US6923986B2Multiblock biodegradable hydrogels for drug delivery and tissue treatmentGENZYME CORP·Filed 2003·Granted Aug 2, 2005·63 cites·13 claims
- 1597US6858203B2Method of making phosphate-binding polymers for oral administrationGENZYME CORP·Filed 2002·Granted Feb 22, 2005·85 cites·18 claims
- 1697US6855830B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2002·Granted Feb 15, 2005·67 cites·2 claims
- 1797US6733780B1Direct compression polymer tablet coreGENZYME CORP·Filed 2000·Granted May 11, 2004·122 cites·19 claims
- 1897US6099832ATransplants for myocardial scarsGENZYME CORP·Filed 1998·Granted Aug 8, 2000·259 cites·23 claims
- 1997US5882877AAdenoviral vectors for gene therapy containing deletions in the adenoviral genomeGENZYME CORP·Filed 1997·Granted Mar 16, 1999·338 cites·21 claims
- 2097US5670488AAdenovirus vector for gene therapyGENZYME CORP·Filed 1993·Granted Sep 23, 1997·358 cites·19 claims
- 2196US12434008B1Lock ring for a medicament delivery deviceGENZYME CORP·Filed 2025·Granted Oct 7, 2025·2 cites·21 claims
- 2296US11878024B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2022·Granted Jan 23, 2024·3 cites·6 claims
- 2396US11406644B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2020·Granted Aug 9, 2022·5 cites·21 claims
- 2496US11130816B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2019·Granted Sep 28, 2021·6 cites·20 claims
- 2596US10836813B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2017·Granted Nov 17, 2020·11 cites·23 claims
- 2696US10369193B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2016·Granted Aug 6, 2019·17 cites·13 claims
- 2796US9657056B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2015·Granted May 23, 2017·22 cites·29 claims
- 2896US8007780B2AAV vectors for gene delivery to the lungGENZYME CORP·Filed 2008·Granted Aug 30, 2011·69 cites·7 claims
- 2996US7863293B2CXCR4 chemokine receptor binding compoundsGENZYME CORP·Filed 2007·Granted Jan 4, 2011·24 cites·18 claims
- 3096US7763738B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2007·Granted Jul 27, 2010·28 cites·5 claims
- 3196US7455248B2Powder delivery deviceGENZYME CORP·Filed 2005·Granted Nov 25, 2008·63 cites·23 claims
- 3296US7371366B2GlcNAc phosphotransferase of the lysosomal targeting pathwayGENZYME CORP·Filed 2005·Granted May 13, 2008·31 cites·2 claims
- 3396US7196205B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2005·Granted Mar 27, 2007·51 cites·16 claims
- 3496US7087583B2Sequence specific DNA binding by p53GENZYME CORP·Filed 2001·Granted Aug 8, 2006·64 cites·16 claims
- 3596US7008635B1Hydrogels for orthopedic repairGENZYME CORP·Filed 2000·Granted Mar 7, 2006·93 cites·15 claims
- 3696US7001994B2Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteinsGENZYME CORP·Filed 2002·Granted Feb 21, 2006·84 cites·19 claims
- 3796US6682730B2Transplants for myocardial scarsGENZYME CORP·Filed 2002·Granted Jan 27, 2004·68 cites·12 claims
- 3896US6432927B1Compositions and methods for inducing gene expressionGENZYME CORP·Filed 2000·Granted Aug 13, 2002·62 cites·31 claims
- 3996US6419928B1Monoclonal antibodies to transforming growth factor-beta and methods of useGENZYME CORP·Filed 2000·Granted Jul 16, 2002·84 cites·9 claims
- 4096US5948767ACationic amphiphile/DNA complexesGENZYME CORP·Filed 1996·Granted Sep 7, 1999·271 cites·13 claims
- 4196US5824544AAdenovirus vectors for gene therapyGENZYME CORP·Filed 1995·Granted Oct 20, 1998·261 cites·6 claims
- 4295US12110338B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2021·Granted Oct 8, 2024·2 cites·29 claims
- 4395US11807690B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2019·Granted Nov 7, 2023·4 cites·17 claims
- 4495US10995148B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2015·Granted May 4, 2021·8 cites·39 claims
- 4595US10954230B2Method of preparing glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2020·Granted Mar 23, 2021·4 cites·3 claims
- 4695US9650413B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2015·Granted May 16, 2017·22 cites·37 claims
- 4795US9650412B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2014·Granted May 16, 2017·34 cites·26 claims
- 4895US9492415B2Methods of treating Parkinson's disease using viral vectorsGENZYME CORP·Filed 2012·Granted Nov 15, 2016·16 cites·8 claims
- 4995US9415119B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2015·Granted Aug 16, 2016·13 cites·7 claims
- 5095US7935692B2Methods to mobilize progenitor/stem cellsGENZYME CORP·Filed 2005·Granted May 3, 2011·29 cites·26 claims
Showing the top 50 of 1,085 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →